

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

pSb_init containing anti SARS-CoV-2_RBD sybody Sb#45

RRID:Addgene_153526

Type: Plasmid

Proper Citation

RRID:Addgene_153526

Plasmid Information

URL: <http://www.addgene.org/153526>

Proper Citation: RRID:Addgene_153526

Insert Name: Sb#45

Organism: Synthetic

Bacterial Resistance: Chloramphenicol

Vector Backbone Description: Vector Backbone:pSB_init; Vector Types:Bacterial Expression; Bacterial Resistance:Chloramphenicol

Comments: Please visit <https://www.biorxiv.org/content/10.1101/2020.04.16.045419v1> for BioRxiv preprint

Plasmid Name: pSb_init containing anti SARS-CoV-2_RBD sybody Sb#45

Record Creation Time: 20220422T221840+0000

Record Last Update: 20260905T074950+0000

Ratings and Alerts

No rating or validation information has been found for pSb_init containing anti SARS-CoV-2_RBD sybody Sb#45.

No alerts have been found for pSb_init containing anti SARS-CoV-2_RBD sybody Sb#45.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Walter JD, et al. (2022) Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. EMBO reports, 23(4), e54199.

Ahmad J, et al. (2021) Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. The Journal of biological chemistry, 297(4), 101202.

Azad T, et al. (2021) SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. Biosensors & bioelectronics, 180, 113122.

Ahmad J, et al. (2021) Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes. bioRxiv : the preprint server for biology.

Ahmad J, et al. (2021) Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants. Research square.